Evaluation of side effects after nicotine nasal spray in patients with chronic rhinitis.
Thirty-three subjects with chronic rhinitis used nicotine nasal spray in an open study as an aid in smoking cessation. Thirty-eight percent of them were completely abstinent at 12 weeks, whereas 35% were completely abstinent at 20 weeks. The nasal spray was associated with irritant nasal side effects, which occurred most often in the early stages of treatment. Clinical nasal examinations could not observe any significant impairment in nasal conditions following spray use. In conclusion, this study confirms the short-term safety of the nicotine nasal spray as an aid in smoking cessation.
Bende
M
M
Allergy Center, Central Hospital, Skövde. bende@sb.artech.se
Burian
P
P
Danielsson
G P
GP
Kruse
E
E
Millqvist
E
E
Säwe
U
U
D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D000368:Aged; D002467:Cell Nucleus / Q000648:ultrastructure; D002908:Chronic Disease; D002923:Cilia / Q000648:ultrastructure; D003593:Cytoplasm / Q000648:ultrastructure; D004847:Epithelial Cells / Q000473:pathology; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D020397:Goblet Cells / Q000473:pathology; D006801:Humans; D007509:Irritants / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects / Q000473:pathology; D009538:Nicotine / Q000008:administration & dosage / Q000009:adverse effects*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D009666:Nose / Q000473:pathology / Q000503:physiopathology; D010366:Peak Expiratory Flow Rate / Q000502:physiology; D012220:Rhinitis / Q000503:physiopathology*; D012449:Safety; D012903:Smell / Q000502:physiology; D012907:Smoking / Q000473:pathology / Q000503:physiopathology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention
D000336:Aerosols; D007509:Irritants; D018722:Nicotinic Agonists; D009538:Nicotine